Drug Trial Radar · NCT06309277
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Feb 1, 2024
Primary completion
Mar 4, 2025
Study completion Mar 27, 2025
Sponsor
- Lead sponsor
- Gilgamesh PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
Conditions
- Major Depressive Disorder
Interventions
GM-1020Drug
N-methyl-D-aspartate (NMDA) receptor antagonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse EventsTime frame: Baseline, Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MAC Clinical Research
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.